Alleviating the negative effects of cancer may be imminent. Two big pharmaceutical companies Merck and Moderna came together. Ddeveloping a vaccine against cancer. Designed for high-risk melanoma patients, this vaccine was created from technology developed for injections against coronavirus.

great scientific progress found in the second of three articles The final decision on its evolution and conservation is expected by the fourth quarter of this year, as the pharmaceutical company Moderna reported in a note.

scientists based on mRNA technology It serves to teach patients to fight and reject this type of cancer, which is one of the most common and serious cancers to form in cells that produce melanin, which uses parts of the genetic code of this type of tumor.

cancer vaccine given to patients who have had surgery to prevent tumors from coming back. Although it is the same cancer, it does not affect all people equally, so no two injections will be the same, as the pharmaceutical companies confirm. That is, it is tailored to each patient to produce T cells, which are an essential part of the body’s immune response, based on the tumor-specific mutation signature.

Although it’s a revolution in oncology, customizing it to each client can mean treatment is too expensive. Similar cancer vaccines being tested they cost around 100,000 euros per dose.

If the results are positive and the vaccine is approved, the two pharmaceutical companies will share the profits and commercial and manufacturing costs, given that Moderna and Merck founded it in 2016. agreements to co-create personalized vaccines against various types of cancer.

• How the astroturfing or disinformation industry manages to manipulate us

cancer vaccine

about a programmed death receptor-1 therapy (PD-1) works by increasing the body’s immune system’s ability to help detect and fight tumor cells. These doses are humanized monoclonal antibodies that block the interaction between PD-1 and its ligands PD-L1 and PD-L2, thereby activating T lymphocytes that can affect both tumor cells and healthy cells.

The first step in creating a vaccine with these characteristics is identification of genetic mutations in infected cells of the patient because they are able to release missing or defective proteins from cancer cells called neoantigens.

The computer algorithms created will be responsible for seeing which neoantigens are most suitable. hold on to white blood cells and start building an immune response Against defective cells Scientists hope that this vaccine, which can consist of 34 different neoantigens, will activate white blood cells and recognize cancer cells.